679809-58-6

679809-58-6 structure

Name: Enoxaparin sodium
Chemical Name: Enoxaparin sodium
CAS Number: 679809-58-6
Molecular Formula: C₂₆H₄₂N₂O₃₇S₅
Molecular Weight: 1134.92788
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2018-02-04 08:00:00
Modify Date: 2024-01-02 21:35:38
Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19[1][2][3].

Name	Enoxaparin sodium
Synonyms	Clexane Enoxaparin Enoxil Klexane Lovenox

Description	Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19[1][2][3].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Thrombin Research Areas >> Infection Signaling Pathways >> Anti-infection >> SARS-CoV Research Areas >> Inflammation/Immunology Research Areas >> Neurological Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Factor Xa
In Vitro	Enoxaparin (0-70 µg/mL, 90 min) enhances AAT (alpha-1-antitrypsin) inhibition of both TMPRSS2 (Transmembrane Protease 2) activity and infection of hAEc (human airway epithelial cells) with HCoV-229E[1]. Cell Viability Assay[1] Cell Line: HEK293T TMPRSS2 cells, hAEc Concentration: 0, 8.8, 35, 70 µg/mL Incubation Time: 90 min Result: Significantly inhibited TMPRSS2 activity at the 90 min incubation period at 35 and 70 µg/mL, enhanced AAT inhibition of TMPRSS2 activity, and augmented AAT inhibition of HCoV-229E infection of hAEc.
In Vivo	Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat[2]. Animal Model: Adult male Wistar rats (350-450 g, TBI-treated)[2] Dosage: 0 mg/kg, 1 mg/kg Administration: SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction. Result: Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active caspase-3 overexpressions as well as neurodegeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat.
References	[1]. Bai X, et al. Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. Sci Rep. 2022 Mar 25;12(1):5207. [2]. Župan Ž, et al. Effects of enoxaparin in the rat hippocampus following traumatic brain injury. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1846-56. [3]. Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May;5(3):387-99.

Molecular Formula	C₂₆H₄₂N₂O₃₇S₅
Molecular Weight	1134.92788
Storage condition	-20℃

679809-58-6	9041-08-1
1144097-30-2	68057-99-8
6100-16-9	79060-88-1
30605-57-3	61538-65-6
71376-34-6	91840-27-6
1158522-08-7	20292-02-8
940364-43-2	1447607-65-9
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1354952-92-3